PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Negative EBIT growth while TRAW is at 16.10%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
27.06%
Operating income growth above 1.5x TRAW's 16.10%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-304.05%
Negative net income growth while TRAW stands at 15.38%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-302.06%
Negative EPS growth while TRAW is at 36.60%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-288.66%
Negative diluted EPS growth while TRAW is at 36.60%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.11%
Share reduction more than 1.5x TRAW's 33.46%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.68%
Diluted share reduction more than 1.5x TRAW's 33.46%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
56.08%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
56.11%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-17391.51%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-1778.39%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-42866.91%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-15208.07%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-5247.61%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
4590.00%
Equity/share CAGR of 4590.00% while TRAW is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
1682.71%
Equity/share CAGR of 1682.71% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1405.22%
Equity/share CAGR of 1405.22% while TRAW is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Positive asset growth while TRAW is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
247.25%
Positive BV/share change while TRAW is negative. John Neff sees a clear edge over a competitor losing equity.
-50.51%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-53.09%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
3.56%
We expand SG&A while TRAW cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.